CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax of $53.17 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2026-06-27 was $53.17M, a 25.55% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2026-03-28 was -$29.94M, a 183.22% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2025-12-27 was -$294.10M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2025-09-27 was $87.20M, a 4.43% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2025 was -$99.50M, a 206.86% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2024 was $93.11M, a 83.98% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2023 was $581.28M, a 6.69% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2022 was $622.99M, a 29.60% increase from fiscal 2021.
| Period end | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 3 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 6 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 9 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 12 month |
|---|---|---|---|---|
| 2026-06-27 | $53.17M 10-Q · filed 2026-08-05 | $23.23M 10-Q · filed 2026-08-05 | -$270.87M derived: sum of 3 quarters · filed 2026-08-05 | -$183.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | -$29.94M 10-Q · filed 2026-05-07 | -$324.04M derived: sum of 2 quarters · filed 2026-05-07 | -$236.84M derived: sum of 3 quarters · filed 2026-05-07 | -$165.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | -$294.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$206.90M derived: sum of 2 quarters · filed 2026-02-18 | -$135.48M derived: sum of 3 quarters · filed 2026-08-05 | -$99.50M 10-K · filed 2026-02-18 |
| 2025-09-27 | $87.20M 10-Q · filed 2025-11-05 | $158.62M derived: sum of 2 quarters · filed 2026-08-05 | $194.60M 10-Q · filed 2025-11-05 | -$22.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $71.42M 10-Q · filed 2026-08-05 | $107.40M 10-Q · filed 2026-08-05 | -$109.39M derived: sum of 3 quarters · filed 2026-08-05 | -$18.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $35.98M 10-Q · filed 2026-05-07 | -$180.81M derived: sum of 2 quarters · filed 2026-05-07 | -$89.57M derived: sum of 3 quarters · filed 2026-05-07 | $30.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | -$216.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$125.55M derived: sum of 2 quarters · filed 2026-02-18 | -$5.90M derived: sum of 3 quarters · filed 2026-02-18 | $93.11M 10-K · filed 2026-02-18 |
| 2024-09-28 | $91.24M 10-Q · filed 2025-11-05 | $210.89M derived: sum of 2 quarters · filed 2025-11-05 | $309.90M 10-Q · filed 2025-11-05 | $518.61M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | $119.65M 10-Q · filed 2025-08-06 | $218.66M 10-Q · filed 2025-08-06 | $427.37M derived: sum of 3 quarters · filed 2026-02-18 | $540.24M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $99.01M 10-Q · filed 2025-05-07 | $307.72M derived: sum of 2 quarters · filed 2026-02-18 | $420.59M derived: sum of 3 quarters · filed 2026-02-18 | $549.25M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $208.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $321.58M derived: sum of 2 quarters · filed 2026-02-18 | $450.24M derived: sum of 3 quarters · filed 2026-02-18 | $581.28M 10-K · filed 2026-02-18 |
| 2023-09-30 | $112.87M 10-Q · filed 2024-11-06 | $241.54M derived: sum of 2 quarters · filed 2024-11-06 | $372.58M 10-Q · filed 2024-11-06 | $617.50M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-07-01 | $128.66M 10-Q · filed 2024-08-07 | $259.70M 10-Q · filed 2024-08-07 | $504.63M derived: sum of 3 quarters · filed 2025-02-19 | $627.73M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-04-01 | $131.04M 10-Q · filed 2024-05-09 | $375.96M derived: sum of 2 quarters · filed 2025-02-19 | $499.07M derived: sum of 3 quarters · filed 2025-02-19 | $643.18M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $244.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $368.03M derived: sum of 2 quarters · filed 2025-02-19 | $512.14M derived: sum of 3 quarters · filed 2025-02-19 | $622.99M 10-K · filed 2025-02-19 |
| 2022-09-24 | $123.11M 10-Q · filed 2023-11-08 | $267.22M derived: sum of 2 quarters · filed 2023-11-08 | $378.07M 10-Q · filed 2023-11-08 | $541.71M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-25 | $144.11M 10-Q · filed 2023-08-09 | $254.96M 10-Q · filed 2023-08-09 | $418.60M derived: sum of 3 quarters · filed 2024-02-14 | $541.87M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-26 | $110.85M 10-Q · filed 2023-05-11 | $274.49M derived: sum of 2 quarters · filed 2024-02-14 | $397.76M derived: sum of 3 quarters · filed 2024-02-14 | $525.25M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-25 | $163.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $286.91M derived: sum of 2 quarters · filed 2024-02-14 | $414.41M derived: sum of 3 quarters · filed 2024-02-14 | $480.71M 10-K · filed 2024-02-14 |
| 2021-09-25 | $123.27M 10-Q · filed 2022-11-02 | $250.77M derived: sum of 2 quarters · filed 2022-11-02 | $317.07M 10-Q · filed 2022-11-02 | |
| 2021-06-26 | $127.50M 10-Q · filed 2022-08-03 | $193.80M 10-Q · filed 2022-08-03 | ||
| 2021-03-27 | $66.30M 10-Q · filed 2022-05-04 | |||
| 2020-09-26 | $135.28M 10-Q · filed 2021-11-03 | $219.23M derived: sum of 2 quarters · filed 2021-11-03 | $274.69M 10-Q · filed 2021-11-03 | |
| 2020-06-27 | $83.95M 10-Q · filed 2021-08-04 | $139.41M 10-Q · filed 2021-08-04 | ||
| 2020-03-28 | $55.46M 10-Q · filed 2021-05-04 | |||
| 2019-09-28 | $73.23M 10-Q · filed 2020-10-29 | $132.23M derived: sum of 2 quarters · filed 2020-10-29 | $198.52M 10-Q · filed 2020-10-29 | |
| 2019-06-29 | $58.99M 10-Q · filed 2020-08-05 | $125.28M 10-Q · filed 2020-08-05 | ||
| 2019-03-30 | $66.29M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |